폐경과 비만 여부에 따른 ghrelin, adiponectin, 유산소능력의 차이와 신체조성지표들 간의 관련성
The Differences of Ghrelin, Adiponectin, and Aerobic Capacity by Menopause and Obesity and its Inter-Correlation with Body Composition Indexes
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
본 연구는 폐경과 비만 여부에 따라 ghrelin, adiponectin이 어떠한 차이를 나타내며, 이들 호르몬이 유산소능력과 신체조성 지표들과 어떠한 관련이 있는지를 규명하기 위한 것이다. 피험자는 모두 여성으로 BMI 30 kg/m2 이상 또는 체지방율 25%를 기준으로 비 비만과 비만 집단으로, 그리고 폐경 여부에 따라 폐경전, 폐경 집단으로 구분하였다. G1은 폐경전-비 비만(44.1±5.6 yrs, n=10,), G2는 폐경전의 비만(42.5±7.8 yrs, n=10), G3은 폐경-비 비만(51.4±4.8 yrs, n=17), G4는 폐경-비만(54.0±3.6, n=18)으로 구성하였다. 유산소능력의 평가를 위하여 VO2max를 산출하였고 신체조성지표(body composition index)의 평가를 위하여 체중, BMI, %BF, WC, WHR를 측정, 산출하였다. 비만과 폐경 여부에 따라 각각 VO2max, ghrelin, adiponectin의 차이를 알아보기 위하여 independent t-test를 사용하였다. 집단간의 VO2max, ghrelin, adiponectin 차이를 비교하기 위하여 Two-Way ANOVA를 사용하였으며, 모든 피험자 신체조성지표와 유산소능력 그리고 ghrelin과 adiponectin간의 관련성을 분석하기 위하여 pearson's correlation을 산출하였다. 비만 여부에 따라서 adiponectin은 유의한 차이가 나타났으며(F=2.4, Sig=.03, p<.05), 폐경 여부에 따른 차이는 유의하지 않은 것으로 나타났다. VO2max G2와 G3 간에 유의한 차이가 나타났으며(f=2.95, Sig=.041, p<.05), ghrelin과 adiponectin의 그룹간의 차이는 유의하지 않았다. ghrelin은 유산소능력과 유의한 상관관계를(r=.315, Sig=.019, p<.05) 그리고 adiponectin은 BMI(r=-.414, Sig=.002, p<.01), 체중(r=-.317, r=.019, p<.05), 체지방율(r=-.361, Sig=.007. p<.01), WC(r=-.358, Sig=.007, p<.01), WHR(r=.423, Sig=.001, p<.01)와 유의한 상관관계를 나타냈다. 이러한 연구결과가 의미하는 것은 폐경을 한 경우 신체조성의 지표들을 모니터링 함으로써 심혈관 질환의 위험요인인 adiponectin을 관리할 수 있을 것이며, 폐경 여부와 관계없이 비만 여성의 경우는 유산소능력을 향상시키는 운동을 실시함으로써 심혈관질환의 위험도를 낮출 수 있을 것으로 사료된다.
Abstract
The purpose of this study was to investigate the differences of ghrelin ,adiponectin, and aerobic capacity by menopause and obesity, and also to exam the inter-relationship among the above three factors and body composition indexes. Female subjects participated in this study and they were classified by BMII>30 and %BF>25% as normal weight and obesity groups, and by menopause state as pre-menopause and menopause groups. G1 is defined as pre-menopause and non-obese (44.1±5.6 yrs, n=10), G2 is as pre-menopause and obese (42.5±7.8 yrs, n=10), G3 is as menopause and non-obese (51.4±4.8 yrs, n=17), and G4 is as menopause and obese (54.0±3.6, n=18). VO2max was estimated as an aerobic capacity, and weight, BMI, %BF, WC, WHR were estimated as body composition indexes. Independent t-test was performed to compare the differences of aerobic capacity, ghrelin, and adiponectin by obesity and menopause state. Two-way ANOVA was utilized to compare ghrelin, adiponectin, and VO2max differences by groups. Also, peason's correlations were used in total subjects to produce the inter-correlations between ghrelin, adiponectin and VO2max, body composition indexes. As results, adiponectin was significantly different by obesity. VO2max was significantly different between G2 and G3. There were significant correlation between ghrelin and VO2max. Also, significant correlations between adiponectin and BMI, body weight, %BF, waist circumference, waiast & hip ratio. These results indicate that management of cardiovascular risk factors, diponectin, would be possible by monitoring body composition indexes in menopaused woman. Furthermore, enhancing aerobic capacity can be used as therapy strategy in order to decrease cardiovascular risk.
참고문헌 (38)
- ACSM's Guidelines for Exercise Testing and Prescription, , pp.74~ (2006), Lippincott Williams & Wilkins
- Anker, S. D, "Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation", Chest, 115, pp.836~847 (1999)
- Arita, Y, "Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity", Biochemical and biophysical research communications, 257, pp.79~83 (1999)
- Ariyasu, H, "Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immuno-reactivity levels in humans", Journal of Clinical Endocrinology and Metabolism, 86, pp.4547~4571 (2001)
- Berg, A. H, "ACR30", adiponectine: an adipokine regulating glucose and lipid metabolism, 2002, pp.13, 84~89
- Broglio, F, "The endocrine response to ghrelin as function of gender and age in humans", 84th Annual Meeting, pp.3~556 (2002)
- Erdmann, J, "Plasma ghrelin levels during exercise - effects of intensity and", Regulatory peptides, 143, pp.127~135 (2007)
- Foster-Schubert, K, "Human plasma ghrelin levels increase during a one-year exercise program", The Journal of Clinical Endocrinology and Metabolism, 90, pp.820~825 (2005)
- Hansen, T. K, "Weight loss increases circulating levels of ghrelin in human obesity", Clinical Endocrinology, 56, pp.203~206 (2002)
- Holdstock, C, "Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans", Journal of Clinical Endorinology and Metabolism, 88, pp.3177~3183 (2003)
- Iwamoto, I, "Menopausal status influences the relationship between serum ghrelin levels and fat mass in healthy women", Journal of endocrinological investigation, 28, pp.405~409 (2005)
- James, P. T, "The worldwide obesity epidemic", Obesity Research, 9(4), pp.228S~233S (2001)
- Jürimäe, J, "Plasma adiponectin concentration in healthy pre- and postmenopausal women: relationship with body composition, bone mineral, and metabolic variables", American Journal of Physiology, 293(1), pp.E42~E47 (2007)
- Katsuki, A, "Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus", European Journal of Endocrinology, 151, pp.573~577 (2004)
- Killokoski, E, "Estrogen replacement therapy increases plasma ghrelin levels", The Journal of Clinical Endocrinology and Metabolis, 90, pp.2954~2963 (2005)
- Kumada, M, "Adiponectin specifically increased tissue inhibitor of metalloprotenase-1 through interleukin-10 expression in human macrophages", Circulation, 109, pp.2046~2049 (2004)
- Leidy, H. J, "Circulating ghrelin is sensitive to changes in body weight during a diet and exercise program in normal-weight young women", The Journal of clinical endocrinology and metabolism, 89, pp.2659~2664 (2004)
- Locatelli, V, "Growth hormone-independent cardioprotective effects of hexarelin in the rat", Endocrinology, 140, pp.4024~4031 (1999)
- Marcell, T. J, "Exercise training is not associated with improved levels of C-reactive protein or adiponectin", Metabolism, 54, pp.533~541 (2005)
- Monzillo, L. U, "Effect of lifestyle modification on adipokine levels in obese subject with insulin resistance", Obesity Research, 11, pp.1048~1054 (2003)
- Nagaya, N, "Ghrelin, a novel growth hormone releasing peptide, in the treatment of chronic heart failure", Regulatory Peptides, 114, pp.71~77 (2003)
- Nagaya, M, "Hemodynamic and hormonal effects of human ghrelin in healthy volunteer", American Journal of Physiology, 280, pp.R1483~R1487 (2001)
- Nagaya, N, "Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure", Circulation, 104, pp.1430~1435 (2001)
- Nishizawa, H, "Androens decrease plasma adiponectin, and insulin-sensitizing adipocyte derived protein", Diabetes, 51, pp.2734~2741 (2002)
- Ouchi, N, "Adipocyte-derived plasma protein, adiponectin, suppress lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages", Circulation, 103, pp.1057~1063 (2001)
- Pajavani, U. B, "Adiponectin: systemin contributor to insulin sensitivity", Current Diabetes Reports, 3, pp.207~213 (2003)
- Pistola, T, "Plasma adiponectin levels and risk of myocardial infarction in men", Journal of the American Medical Association, 291, pp.1730~1763 (2004)
- Ravussin, E, "Plasma ghrelin concentration and energy balance: overfeeding and negative energy balance studies in twins", The Journal of Clinical Endocrinology and Metabolism, 86, pp.4547~4551 (2001)
- Rigamonti, A. E, "Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients", The Journal of Endocrinology, 175(1), pp.R1~R5 (2002)
- Schmidt, A, "Acute exercise has no effect on ghrelin plasma concentrations", Hormone and Metabolic Research, 36, pp.174~177 (2004)
- Shiiya, T, "Plasma ghrelin levels in lean and obese hunmans and the effect of glucose on ghrelin secretion", The Journal of Clinical Endocrinology and Metabolism, 87(1), pp.240~244 (2002)
- Shintani, M, "Ghrelin,an endogenous growth hormone secretagogue is a novel orexigenic peptid that antagonizes leptin action through the activation of hypothalamic neuropeptide Y", Y1 receptor pathway, 2001, pp.50, 227~232
- Sowers, M. F. R, "Change in adipocytokines and ghrelin with menopause.The European Menopause", Journal, 59, pp.149~157 (2008)
- Tschöp, M, "Circulating ghrelin levels are decreased in human obesity", Diabetes, 50(4), pp.707~709 (2001)
- Turcato, E, "Waist circumference and abdominal sagittal diameter as surrogates of body fat distribution in the elderly:Their relation with cardiovascular risk factors.International Journal of Obesity and Related Metabolic", Disorders, 24, pp.1005~1010 (2000)
- Yamauchi, T, "The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity", Nature Medicine, 7, pp.941~946 (2001)
- Wren, A. M, "Ghrelin enhances appetite and increases food intake in humans", The Journal of Clinical Endocrinology and Metabolism, 86, pp.5992~ (2001)